Amedeo Biasi

I am a molecular and medical Biotechnologist fascinated by the computational approach toward the biological world. I attained my bachelor’s degree in biotechnology at the University of Verona by producing and characterizing two mutants of the human Histidine Decarboxylase (hHDC) in the research group of Prof. Mariarita Bertoldi. During this thesis project I’ve been able to engage different biophysical approaches like Circular Dicroism and Dynamic Light Scattering among others.

Immediately after I enrolled for the master’s degree in molecular and Medical Biotechnology at the University of Verona where I got in touch and got interested in the computational biology field. Thanks to Prof. Alejandro Giorgetti I took advantage of the wonderful opportunity offered by the Erasmus+ project by which I’ve been able to develop my master’s thesis at the Laboratory of Computational Medicine of the Universitat Autonoma de Barcelona under the supervision of Prof. Leonardo Pardo and Dott. Arnau Cordomì. By means of different computational approaches I investigated the conformation of cannabinoid receptor 2 (CB2R), the binding mode of a positive allosteric modulator with/without an orthosteric antagonist to it and the simulation of the whole system over time to assess its reliability and stability.

From Febrary 2020 to October 2020 I’ve been part of the Biochemistry and Molecular Biophysics group where Prof. Daniele Dell’Orco offered me a fellowship, giving me the chance to merge my interest in both the biological and computational worlds. During this period, I had the opportunity to work on a project funded by the Verona Brain Research Foundation entitled “Molecular design of nanovescicles for protein-replacement in the treatment of retinal dystrophies”.

From October 2020 I enrolled in the Biomolecular Medicine PhD course at the University of Verona and I earned a PhD. position in Prof. Dell’Orco’s laboratory. Here, by working on the biophysical, biochemical and in silico characterization of Guanylate Cyclase Activating Protein 1’s (GCAP1) mutants and protein/DNA loaded liposomes for protein-replacement therapies, I have the opportunity to enhance even more my laboratory skills.